Alirocumab Articles

Articles
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial
Goodman SG, Steg PG, Poulouin Y, et al.
Journal:
J Am Heart Assoc

First published: September 13, 2023 DOI: 10.1161/JAHA.122.029216
View
- Share
Articles
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
Pérez de Isla L, Díaz-Díaz JL, Romero MJ, et al.
Journal:
Circulation

First published: April 3, 2023 DOI: 10.1161/CIRCULATIONAHA.122.062557
View
- Share
Articles
Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care
Bhatt DL
Journal:
EuroIntervention

First published: December 2, 2022 DOI: 10.4244/EIJ-E-22-00047
View
- Share
Articles
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab
Schwartz G, Szarek M, Zeiher A, et al.
Journal:
J Am Coll Cardiol

First published: October 31, 2022 DOI: 10.1016/j.jacc.2022.09.035
View
- Share
Articles
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Hagström E, Steg PG, Szarek M, et al.
Journal:
Circulation

First published: June 30, 2022 DOI: 10.1161/CIRCULATIONAHA.121.057807
View
- Share
Articles
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
Landmesser U, McGinniss J, Steg PG, et al.
Journal:
Eur J Prev Cardiol

First published: June 16, 2022 DOI: 10.1093/eurjpc/zwac107
View
- Share
Articles
Alirocumab after acute coronary syndrome in patients with a history of heart failure
White HD, Schwartz GG, Szarek M, et al.
Journal:
Eur Heart J

First published: April 21, 2022 DOI: 10.1093/eurheartj/ehab804
View
- Share
Articles
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial
Räber L, Ueki Y, Otsuka T, et al.
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5218
View
- Share
Articles
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
Ostadal P, Steg PG, Poulouin Y, et al.
Journal:
Lancet Diabetes Endocrinol

First published: April 1, 2022 DOI: 10.1016/S2213-8587(22)00043-2
View
- Share

Alirocumab Articles

Articles

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman SG, Steg PG, Poulouin Y, et al.

Articles

Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

Pérez de Isla L, Díaz-Díaz JL, Romero MJ, et al.

Articles

Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care

Bhatt DL

Articles

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

Schwartz G, Szarek M, Zeiher A, et al.

Articles

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström E, Steg PG, Szarek M, et al.

Articles

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

Landmesser U, McGinniss J, Steg PG, et al.

Articles

Alirocumab after acute coronary syndrome in patients with a history of heart failure

White HD, Schwartz GG, Szarek M, et al.

Articles

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial

Räber L, Ueki Y, Otsuka T, et al.

Articles

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ostadal P, Steg PG, Poulouin Y, et al.

Articles

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman SG, Steg PG, Poulouin Y, et al.

Share

Articles

Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

Pérez de Isla L, Díaz-Díaz JL, Romero MJ, et al.

Share

Articles

Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care

Bhatt DL

Share

Articles

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

Schwartz G, Szarek M, Zeiher A, et al.

Share

Articles

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström E, Steg PG, Szarek M, et al.

Share

Articles

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

Landmesser U, McGinniss J, Steg PG, et al.

Share

Articles

Alirocumab after acute coronary syndrome in patients with a history of heart failure

White HD, Schwartz GG, Szarek M, et al.

Share

Articles

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial

Räber L, Ueki Y, Otsuka T, et al.

Share

Articles

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ostadal P, Steg PG, Poulouin Y, et al.

Share